ALEXIS Biochemicals: TACI (human):Fc (human) (recombinant)

ALX-522-033

Revised 27-Jun-06

TACI (human):Fc (human) (recombinant)
SYNONYMS	Transmembrane Activator and CAML Interactor (human):Fc (human) (recombinant) TNFRSF 13B (human):Fc (human) (recombinant) CD267 (human):Fc (human) (recombinant)
PRODUCT LINE	Chemokines & Cytokines
PRODUCT CATEGORY	TACI

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-522-033-C050		50 µg	370.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human Mouse
MW:	~40kDa (SDS-PAGE)
SOURCE/HOST:	Produced in HEK 293 cells. The extracellular domain of human TACI (aa 2-118) is fused to the Fc portion of human IgG1.
CONCENTRATION:	1mg/ml after reconstitution.
PURITY:	≥95% (SDS-PAGE)
FORMULATION:	Lyophilized. Contains PBS.
ENDOTOXIN CONTENT:	<0.1EU/µg purified protein (LAL test; BioWhittaker).
RECONSTITUTION:	Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.
SPECIFICITY:	Binds human and mouse (weak) BAFF and APRIL.
BIOLOGICAL ACTIVITY:	Blocks the binding of BAFF and APRIL to their receptors BCMA and TACI, inhibiting BAFF-mediated B cell activation.
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Stable for at least 6 months after receipt when stored at -20°C.
HANDLING:	Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.

Product Images

Please click on thumbnails to enlarge.

Product Specific Literature References

T cell costimulation by the TNF ligand BAFF: B. Huard, et al.; J. Immunol. 167, 6225 (2001) Abstract
Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen: P. Schneider, et al.; J. Exp. Med. 194, 1691 (2001) Abstract
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL: B. He, et al.; J. Immunol. 172, 3268 (2004) Abstract; Full Text
BAFF production by antigen-presenting cells provides T cell co-stimulation: B. Huard, et al.; Int. Immunol. 16, 467 (2004) Abstract
Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis: D. Bonci, et al.; Blood 103, 3169 (2004) Abstract; Full Text
APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2: P.K. Mongini, et al.; J. Immunol. 176, 6736 (2006) Abstract

General Information

TACI (transmembrane activator and CAML-interactor) is a 40kDa protein which belongs to the tumor necrosis factor (TNF) receptor family. TACI specifically binds to BAFF and APRIL, two members of the TNF family. Activation of TACI induces recruitment of TNF-R-associated factors (TRAF)-2, -5 and -6 leading to the activation of NFκB, NF-AT and AP1. APRIL and BAFF induce proliferation and IgM secretion. BAFF is involved in the onset of Systemic Lupus Erythematosus (SLE) in mice.
BACKGROUND/TECHNICAL INFORMATION	Swiss-Prot link O14836: TACI (human) AfCS Signalling Gateway link: A002248 TACI (mouse)
MANUFACTURER	Manufactured by Apotech Corporation.

General Literature References

NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily: G.U. von Bulow & R.J. Bram; Science 278, 138 (1997) Abstract
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth: P. Rennert, et al.; J. Exp. Med. 192, 1677 (2000) Abstract
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS: Y. Wu, et al.; J. Biol. Chem. 275, 35478 (2000) Abstract
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI: S.A. Marsters, et al.; Curr. Biol. 10, 785 (2000) Abstract
TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation: X.Z. Xia, et al.; J. Exp. Med. 192, 137 (2000) Abstract
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease: J.A. Gross, et al.; Nature 404, 995 (2000) Abstract